| dc.contributor |
Department of Urology, University of Michigan School of Medicine, Ann Arbor, MI, |
|
| dc.contributor |
* Division of Urology, |
|
| dc.contributor |
Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, |
|
| dc.contributor |
Division of Urology, Duke University School of Medicine, Durham, NC, and |
|
| dc.contributor |
Department of Urology, New York University School of Medicine, New York, NY, USA |
|
| dc.creator |
Megwalu, Ifeanyichukwu I. |
|
| dc.creator |
Ferguson, Genoa G. |
|
| dc.creator |
Wei, John T. |
|
| dc.creator |
Mouraviev, Vladimir |
|
| dc.creator |
Polascik, Thomas J. |
|
| dc.creator |
Taneja, Samir |
|
| dc.creator |
Black, Linda |
|
| dc.creator |
Andriole, Gerald L. |
|
| dc.creator |
Kibel, Adam S. |
|
| dc.date |
2010-06-01T20:23:11Z |
|
| dc.date |
2010-06-01T20:23:11Z |
|
| dc.date |
2008-09 |
|
| dc.date.accessioned |
2022-05-19T13:30:14Z |
|
| dc.date.available |
2022-05-19T13:30:14Z |
|
| dc.identifier |
Megwalu, Ifeanyichukwu I.; Ferguson, Genoa G.; Wei, John T.; Mouraviev, Vladimir; Polascik, Thomas J.; Taneja, Samir; Black, Linda; Andriole, Gerald L.; Kibel, Adam S. (2008). "Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer." BJU International 102(5): 546-550. <http://hdl.handle.net/2027.42/73501> |
|
| dc.identifier |
1464-4096 |
|
| dc.identifier |
1464-410X |
|
| dc.identifier |
http://hdl.handle.net/2027.42/73501 |
|
| dc.identifier |
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18694408&dopt=citation |
|
| dc.identifier |
18694408 |
|
| dc.identifier |
10.1111/j.1464-410X.2008.07832.x |
|
| dc.identifier |
BJU International |
|
| dc.identifier |
Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43 – 66 |
|
| dc.identifier |
Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000; 11: 167 – 70 |
|
| dc.identifier |
Andriole GL, Bullock TL, Belani JS et al. Is there a better way to biopsy the prostate? Prospects for a novel transrectal systematic biopsy approach. Urology 2007; 70: 22 – 6 |
|
| dc.identifier |
Loch T. Urologic imaging for localized prostate cancer in 2007. World J Urol 2007; 25: 121 – 9 |
|
| dc.identifier |
Freedland SJ, Aronson WJ, Csathy GS et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology 2003; 61: 742 – 7 |
|
| dc.identifier |
Presti JC Jr. Prostate biopsy: how many cores are enough? Urol Oncol 2003; 21: 135 – 40 |
|
| dc.identifier |
Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163: 163 – 6 |
|
| dc.identifier |
Presti JC Jr, O’Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 2003; 169: 125 – 9 |
|
| dc.identifier |
Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schroder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60: 826 – 30 |
|
| dc.identifier |
Siddiqui EJ, Ali S, Koneru S. The rectal administration of lignocaine gel and periprostatic lignocaine infiltration during transrectal ultrasound-guided prostate biopsy provides effective analgesia. Ann R Coll Surg Engl 2006; 88: 218 – 21 |
|
| dc.identifier |
de Jesus CM, Correa LA, Padovani CR. Complications and risk factors in transrectal ultrasound-guided prostate biopsies. Sao Paulo Med J 2006; 124: 198 – 202 |
|
| dc.identifier |
Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981 – 90 |
|
| dc.identifier |
Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis – correlation with biopsy and histopathology. J Magn Reson Imaging 2006; 24: 108 – 13 |
|
| dc.identifier |
Kumar V, Jagannathan NR, Kumar R et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/mL. N MR Biomed 2007; 20: 11 – 20 |
|
| dc.identifier |
Gore JL, Shariat SF, Miles BJ et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001; 165: 1554 – 9 |
|
| dc.identifier |
Guichard G, Larre S, Gallina A et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 2007; 52: 430 – 5 |
|
| dc.identifier |
Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 2000; 164: 388 – 92 |
|
| dc.identifier |
Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368 – 74 |
|
| dc.identifier |
Mian BM, Lehr DJ, Moore CK et al. Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology 2006; 67: 379 – 83 |
|
| dc.identifier |
Remzi M, Fong YK, Dobrovits M et al. The Vienna Nomogram. Validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005; 174: 1256 – 60 |
|
| dc.identifier.uri |
http://localhost:8080/xmlui/handle/CUHPOERS/117337 |
|
| dc.description |
To explore the ability of a novel transrectal ultrasonography (TRUS) device (TargetScan TM , Envisioneering Medical Technologies, St. Louis MO) that creates a three-dimensional map of the prostate and calculates an optimal biopsy scheme, to accurately sample the prostate and define the true extent of disease, as standard TRUS-guided prostate biopsy relies on the operator to distribute the biopsy sites, often resulting in under- and oversampling regions of the gland. PATIENTS AND METHODS In a multicentre retrospective chart review evaluating patients who had a TargetScan prostate biopsy between January 2006 and June 2007, we determined the overall cancer detection rate in all patients and in subgroups based on prostate specific antigen level, digital rectal examination, and indication for biopsy. We assessed the pathological significance of cancer detected, defined as a Gleason score of ≥7, positive margins, extracapsular disease or >20% tumour volume in the prostatectomy specimen. We also evaluated the concordance in Gleason score between the biopsy and prostatectomy specimen. RESULTS Cancer was detected in 50 (35.7%) of the 140 patients biopsied, including 39 (47.6%) with no previous biopsies. Of 23 prostatectomy specimens, 20 (87%) had pathologically significant disease. The biopsy predicted the prostatectomy Gleason score in 12 patients (52%), overestimated in two (9%), underestimated in eight (35%), and biopsy Gleason score could not be assigned in one (4%). CONCLUSIONS Template-guided biopsy potentially produces a higher cancer detection rate and more accurate assessment of grade. Prostatectomy specimens did not have a high rate of pathologically insignificant disease. |
|
| dc.description |
Peer Reviewed |
|
| dc.description |
http://deepblue.lib.umich.edu/bitstream/2027.42/73501/1/j.1464-410X.2008.07832.x.pdf |
|
| dc.format |
215346 bytes |
|
| dc.format |
3109 bytes |
|
| dc.format |
application/pdf |
|
| dc.format |
text/plain |
|
| dc.format |
application/pdf |
|
| dc.publisher |
Blackwell Publishing Ltd |
|
| dc.rights |
© 2008 BJU International |
|
| dc.subject |
Prostatic Neoplasms |
|
| dc.subject |
Diagnosis |
|
| dc.subject |
Biopsy |
|
| dc.subject |
Sampling |
|
| dc.subject |
Internal Medicine and Specialties |
|
| dc.subject |
Health Sciences |
|
| dc.title |
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer |
|
| dc.type |
Article |
|